Adenovirus-associated oncolytic virus therapies represent a promising approach to cancer treatment by harnessing the inherent ability of viruses to selectively infect and destroy cancer cells. These therapies utilize genetically modified adenoviruses, which are engineered to target and replicate specifically within tumor cells, leading to their destruction. The modifications often include alterations to the viral genome that enhance its ability to induce a potent immune response against the tumor, while minimizing harm to normal, healthy tissues. This targeted approach not only aims to directly lyse cancer cells but also helps to stimulate a broader anti-tumor immune ...
